| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Evgen Pharma hails 'highly positive' pre-clinical data for brain tumour drug candidate
StockMarketWire.com
|
Drug development company Evgen Pharma said its collaboration with a 'prominent' European university had generated 'highly positive data' for potential brain tumour drug, SFX-01, in pre-clinical trails.
The data showed 'tumour shrinkage and significantly extended survival times. SFX-01 was also found to potentiate (i.e. substantially increase) the therapeutic effect of radiotherapy in these models,' the company said.
'The positive tolerability profile of SFX-01 makes it a viable option for use in addition to current treatments. Our plan is to expand upon these pre-clinical data in this and new collaborations, and start the process of designing an appropriate phase II clinical trial,' it added.
Story provided by StockMarketWire.com
|
|
|
|
|
|
